Other News To Note
Wednesday, July 25, 2012
Camargo Pharmaceutical Services, of Cincinnati, said it completed five pre-investigational new drug meetings last month with the FDA for 505(b)(2) products, including two for India-based pharmaceutical companies. Since 505(b)(2) drugs rely in part on data from already approved therapies, they can be developed and get FDA approval in as little as 30 months with fewer trials and at a lower cost.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.